Trial Protocol ID
USOR 24106_CC-220-MM-002

Investigator
Mohit Narang, MD

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)(Excaliber-RRMM)(CC-220-MM-002)

Trial Protocol ID
USOR 23031_64007957MMY2010

Investigator
Mohit Narang, MD

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific Antibody, in Multiple Myeloma Patients (64007957MMY2010)

Trial Protocol ID
USOR 24073_64007957MMY3006_MajesTEC-9

Investigator
Vinni Juneja, MD

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (MajesTEC-9)

Trial Protocol ID
USOR 22244_IM048022

Investigator
Jose Mendoza, MD

A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)